Filtered By:
Condition: Thrombosis
Education: Study
Procedure: Percutaneous Coronary Intervention
This page shows you your search results in order of date. This is page number 9.
Order by Relevance | Date
Total 597 results found since Jan 2013.
Impact of the ABCD-GENE Score on Clopidogrel Clinical Effectiveness after PCI: A Multi-site, Real-world Investigation
The objective of this study was to validate the ability of ABCD-GENE score to predict risk for atherothrombotic events in a diverse, real-world population of clopidogrel-treated PCI patients who received clinical CYP2C19 genotyping to guide antiplatelet therapy. A total of 2341 adult patients who underwent PCI, were genotyped for CYP2C19, and received treatment with clopidogrel across four institutions were included (mean age 64±12 years, 35% female, 20% Black). The primary outcome was major atherothrombotic events, defined as the composite of all-cause death, myocardial infarction, ischemic stroke, stent thrombosis, or r...
Source: Clinical Pharmacology and Therapeutics - April 16, 2022 Category: Drugs & Pharmacology Authors: Cameron D Thomas Francesco Franchi Ellen C Keeley Joseph S Rossi Marshall Winget R David Anderson Alyssa L Dempsey Yan Gong Megan N Gower Richard A Kerensky Natasha Kulick Jean G Malave Caitrin W McDonough Ian R Mulrenin Petr Starostik Amber L Beitelshees Source Type: research
Impact of Timing and Treatment Strategy on Coronary Perforation During Percutaneous Coronary Intervention for Chronic Total Occlusion
This study aimed to describe the clinical characteristics and timing of perforations during CTO-PCI. Data from the Japanese CTO-PCI expert registry included 8,760 patients who underwent CTO-PCI between January 2014 and January 2019. The major adverse cardiac and cerebrovascular events were defined as death, tamponade, myocardial infarction, stent thrombosis, stroke, and revascularization.
Source: The American Journal of Cardiology - April 14, 2022 Category: Cardiology Authors: Katsuya Miura, Hiroyuki Tanaka, Koichi Kishi, Toshiya Muramatsu, Hisayuki Okada, Yuji Oikawa, Tomohiro Kawasaki, Ryohei Yoshikawa, Atsunori Okamura, Etsuo Tsuchikane Source Type: research
Dual versus triple antithrombotic therapy after percutaneous coronary intervention: the prospective multicentre WOEST 2 Study
CONCLUSIONS: Dual antithrombotic therapy is associated with a substantially lower risk of clinically relevant bleeding without a statistically significant penalty in ischaemic events.PMID:35370126 | DOI:10.4244/EIJ-D-21-00703
Source: EuroIntervention - April 4, 2022 Category: Cardiovascular & Thoracic Surgery Authors: Willem Lambertus Bor Anne Johanna Wilhelmina de Veer Renske H Olie Sem A O F Rikken Dean R P P Chan Pin Yin Jean Paul R Herrman Mathias Vrolix Martijn Meuwissen Tom Vandendriessche Carlos van Mieghem Michael Magro Naoual Bennaghmouch Rick Hermanides Tom A Source Type: research
Neutrophil extracellular traps (NETs) in patients with STEMI. Association with percutaneous coronary intervention and antithrombotic treatments
CONCLUSIONS: NETs were elevated in STEMI patients, increased by pPCI and decreased thereafter. One of the most specific NETs markers was associated with cardiovascular outcomes.PMID:35306431 | DOI:10.1016/j.thromres.2022.03.002
Source: Cell Research - March 20, 2022 Category: Cytology Authors: Maria Ferr é-Vallverdú Ana Mar ía Latorre Mar ía Paz Fuset Elena S ánchez Isabel Madrid Francisco Ten Juana Vall és Mar ía Teresa Santos Santiago Bonanad Antonio Moscard ó Source Type: research
Current status of antithrombotic therapy and in-hospital outcomes in patients with atrial fibrillation undergoing percutaneous coronary intervention in Germany
CONCLUSION: The preferred therapy after PCI in patients with AF is DAT with a NOAC and clopidogrel. In-hospital ischemic and bleeding events were rare. The recommended durations for combination therapy vary considerably.PMID:35243515 | DOI:10.1007/s00059-022-05099-6
Source: Herz - March 4, 2022 Category: Cardiology Authors: Uwe Zeymer Ralph Toelg Harm Wienbergen Hans-Peter Hobbach Alessandro Cuneo Raffi Bekeredjian Oliver Ritter Birgit Hailer Klaus Hertting Marcus Hennersdorf Werner Scholtz Peter Lanzer Harald Mudra Markus Schwefer Peter-Lothar Schwimmbeck Christoph Liebetra Source Type: research
A novel risk score to identify the need for triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention: a post hoc analysis of the RE-DUAL PCI trial
CONCLUSIONS: Our findings support the use of DAT in the majority of patients. A small subgroup of patients might benefit from TAT and we propose a novel clinical risk score to select these patients.PMID:35105533 | DOI:10.4244/EIJ-D-21-00165
Source: EuroIntervention - February 2, 2022 Category: Cardiovascular & Thoracic Surgery Authors: Bastiaan Zwart Willem Lambertus Bor Anne Johanna Wilhelmina Maria de Veer Bakhtawar Khan Mahmoodi Johannes Christiaan Kelder Gregory Y H Lip Deepak L Bhatt Christopher P Cannon Jurri ën Maria Ten Berg Source Type: research
Clinical Outcomes After Percutaneous Coronary Intervention Over Time on the Basis of CYP2C19 Polymorphisms
In conclusion, these data demonstrate a higher risk for ischemic events in patients with 2 CYP2C19 LOF alleles who are prescribed clopidogrel, seen at 3 months after PCI, that is not sustained for 12 months.
Source: Journal of Cardiovascular Pharmacology - February 1, 2022 Category: Cardiology Tags: Original Article Source Type: research
Genotype-Guided Antiplatelet Therapy Versus Standard Therapy for Patients with Coronary Artery Disease: An Updated Systematic Review and Meta-Analysis
CONCLUSION: Genotype-guided antiplatelet treatment could reduce the risk of MACEs without increasing the risk of bleeding events as compared with the standard treatment in patients with CAD or those undergoing PCI. In addition, Genotype-guided antiplatelet treatment might benefit Chinese population or patients with ACS.PMID:34995471 | DOI:10.18433/jpps32140
Source: Journal of Pharmacy and Pharmaceutical Sciences - January 7, 2022 Category: Drugs & Pharmacology Authors: Borui Tang Xin Wang Xinrui Wang Lihong Liu Zhuo Ma Source Type: research
